Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
Official title:
Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study
Verified date | June 2020 |
Source | Hannover Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The ultimate goal is to reduce unnecessary antibiotic prescriptions which drive the development of antibiotic resistance in the community. The primary objective of ABACOPD is to demonstrate in a sufficiently sized clinical study that there is no relevant increase in the "failure-rate" for patients with acute moderate exacerbations of COPD (AE-COPD) treated with placebo instead of antibiotic treatment both on top of standard of care. A patient is classified as treatment failure if additional antibiotic therapy is required during treatment period or until the test of cure visit (TOC at day 30, primary endpoint).
Status | Completed |
Enrollment | 295 |
Est. completion date | June 5, 2019 |
Est. primary completion date | April 23, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Adults, either sex, older or equal than 40 years of age - For female patients, the following conditions are to be met: - has been postmenopausal for at least 1 year, or - is surgically incapable of bearing children, or - is of childbearing potential, and the following conditions are met: - has a negative pregnancy test (urine- or serum-based) immediately before study entry (i.e., before the start of treatment or any other study procedure that could potentially harm the fetus), and one or more of following criteria - must agree to abstinence or use an accepted method of contraception. The subject must agree to continue with the same method throughout the study. - having only female sexual partners - sexual relationship with sterile male partners only - Patients diagnosed with COPD stages I-IV as defined by the Global initiative for chronic Obstructive Lung disease (GOLD). and - Doctor's diagnosis of acute (onset < 7 days) moderate exacerbation of COPD defined by a sustained worsening of the patient's condition (including at least 2 of the following symptoms: increased dyspnea, increased sputum production, sputum purulence and increased cough), from the stable state and beyond normal day-to-day variations, necessitating a change in regular medication in patient with underlying COPD, needing additional medical assistance. - Absence of community acquired pneumonia or lower respiratory tract infection with a clear indication for antibiotic treatment as determined by Procalcitonin level < 0.25 ng/mL and/or absence of pulmonary infiltrates on routine chest x-ray. - Smoking history of at least 10 Pack Years or more. - Patients must be able to complete diaries and quality of life questionnaires. - Patients must sign and date an informed consent prior to any study procedures. Exclusion Criteria: - Severe exacerbation: defined by need for ventilatory support (indicated by severe dyspnea with failure to respond to emergency treatment and/or persistent hypoxemia (PaO2 <50 mm Hg despite O2 administration and / or respiratory acidosis (pH <7.35 and PaCO2> 45mmHg)) or mental confusion or circulatory insufficiency (need of vasopressors) - Fever (>38.5°C) - Known impaired hepatic or renal function - Active or suspected tuberculosis infection of the respiratory tract - Acute exacerbation of asthma - Suspected or known hypersensitivity to, or suspected serious adverse reaction to sultamicillin; suspected or known hypersensitivity to penicillins or cephalosporins - Immunosuppression or Immunosuppressive therapy (cytostatic chemotherapy within last 28 days or neutropenia (neutrophils < 1000/µ)l; systemic corticosteroids (=20 mg prednisolon equivalent/day > 14 days; HIV-infection; immunosuppression after organ- or bone marrow transplant)- Patients with metastatic or hematological malignancy, splenectomized patients or patients with known hyposplenia or asplenia - Oral/parenteral antibiotic use within 30 days prior to randomization (a singular administration of antibiotics prior to randomization is allowed) - In-patient treatment within the last 30 days - An antibiotic is clearly indicated for treatment of a known infection - Known MRSA (methicillin-resistant Staphylococcus aureus) colonization or infection - Patients with known bronchiectasis - Patients with known bacterial airway colonization (>3 positive sputum cultures in the previous year) - Progressively fatal disease, or life expectancy =6 months - Mononucleosis - Lymphatic leukemia - Severe gastro-intestinal disorders with vomiting and diarrhea - Women who are breast feeding - Patients who have received treatment with any other investigational drug within 1 month prior to study entry, or have such treatment planned for the study period during treatment and follow up phase. - Patients with mental conditions rendering them unable to understand the nature, scope, and possible consequences of the study. - Patients unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow up visits, and unlikelihood of completing the study. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsklinikum Aachen | Aachen | |
Germany | Krankenhaus Bad Arolsen | Bad Arolsen | |
Germany | Lungenklinik Ballenstedt | Ballenstedt | |
Germany | Charité - Universitätsmedizin Berlin | Berlin | |
Germany | HELIOS Klinikum Emil von Behring Berlin | Berlin | |
Germany | Pneumologische Praxis am Schloss Charlottenburg Berlin | Berlin | |
Germany | Vivantes Klinikum Neukölln | Berlin | |
Germany | Vivantes Klinikum Spandau | Berlin | |
Germany | Klinikum der Ruhr-Universität Bochum | Bochum | |
Germany | Pneumologische Gemeinschaftspraxis Bonn | Bonn | |
Germany | Forschungszentrum Borstel | Borstel | |
Germany | Klinikum Dortmund gGmbH | Dortmund | |
Germany | Universitätsklinikum Dresden | Dresden | |
Germany | Pneumologische Klinik Waldhof Elgershausen | Elgershausen | |
Germany | Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH | Essen | |
Germany | Praxis Dr. med. Ina Itzigehl Euskirchen | Euskirchen | |
Germany | Universitätsklinikum Freiburg | Freiburg | |
Germany | Universitätsmedizin Greifswald | Greifswald | |
Germany | HELIOS Klinik Hagen-Ambrock | Hagen | |
Germany | Elbpneumologie Hamburg | Hamburg | |
Germany | Schwerpunktpraxis Colonnaden Hamburg | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | Thoraxklinik am Universitätsklinikum Heidelberg | Heidelberg | |
Germany | Universitätsklinikum Heidelberg | Heidelberg | |
Germany | Lungenfachklinik Immenhausen | Immenhausen | |
Germany | Universitätsklinikum Jena | Jena | |
Germany | Universitätsklinikum Schleswig-Holstein Kiel | Kiel | |
Germany | Universitätsklinikum Schleswig-Holstein Campus Lübeck | Lübeck | |
Germany | Brüderkrankenhaus St. Josef Paderborn | Paderborn | |
Germany | Diakoniekrankenhaus Rotenburg | Rotenburg | |
Germany | Krankenhaus Bethanien Solingen | Solingen | |
Germany | HELIOS Klinikum Wuppertal-Barmen | Wuppertal |
Lead Sponsor | Collaborator |
---|---|
Hannover Medical School | CAPNETZ Stiftung |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Assessment of safety: | Key criteria for safety are: adverse events, serious adverse events, changes in physical examination, vital signs, laboratory tests |
up to 1 year | |
Primary | Additional antibiotic therapy to study medication during treatment period or until the test of cure visit (at day 30) | Assessment of additional antibiotic therapy: Patients will be asked at every visit about use of additional antibiotic therapy. In the case of use of additional antibiotic therapy the exact starting date, the active compound, the dose administered, the route of administration,the length of treatment and the indication will be registered. Only additional antibiotic therapy for AE-COPD will be counted as treatment failure. |
up to day 30 | |
Secondary | To evaluate long-term consequences of Placebo treatment | Relapse rate Time to relapse |
up to 1 year | |
Secondary | To assess patient's clinical improvement relative to treatment | Clinical cure rate at the "end of therapy visit" (at day 6) Clinical cure rate at the "test Of cure visit" (at day 30) (both determined by patient-centered outcomes (diary cards)) |
up to 30 days | |
Secondary | To assess additional efficacy endpoints and health outcome evaluations | Changes in COPD Assessment Test(CAT) Changes in Exacerbations of Chronic Pulmonary Disease Tool-Patient reported outcome (EXACT-PRO) Additional antibiotic therapy Time to next exacerbation Number of exacerbations during follow up Per-subject relapse rate at the LFU (Late Follow Up) visits in the subset of subjects in the CE population who were clinically cured at the TOC visit Changes in length of stay in hospital for hospitalized patients All cause mortality |
up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Terminated |
NCT01388920 -
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
|
Phase 2 |